# US 8,278,065 B2 · Polynucleotides encoding anti-GD2 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,065 B2
- Document ID: US8278065B2
- Status: Granted
- Kind: B2
- Application number: 12/494,631
- Filed: 2009-06-30
- Published: 2010-01-14
- Granted: 2012-10-02
- Earliest claimed: 2008-06-30
- Assignees: Morphotek, Inc.
- Inventors: Nicholas C. Nicolaides; Philip M. Sass; Luigi Grasso; Wolfgang Ebel; Yuhong Zhou
- Web page: https://patentgrep.com/patent/US8278065B2

## CPC

- C07K 16/3084: {against tumour-associated gangliosides}
- A61P 35/00: Antineoplastic agents
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.

## Claims

### Claim 1

An isolated polynucleotide encoding an antibody, or antigen binding fragment thereof, that specifically binds to human GD2, having a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 12, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 26, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 28.

### Claim 2 (depends on 1)

The isolated polynucleotide of claim 1, comprising the nucleic acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.

### Claim 3 (depends on 1)

The isolated polynucleotide of claim 1, comprising the nucleic acid sequences of SEQ ID NO: 8 and SEQ ID NO: 24.

### Claim 4 (depends on 1)

The isolated polynucleotide of claim 1, comprising the nucleic acid sequences of SEQ ID NO: 39 and SEQ ID NO: 41.

### Claim 5 (depends on 1)

A vector comprising the isolated polynucleotide of claim 1.

### Claim 6 (depends on 5)

An isolated cell comprising the vector of claim 5.

### Claim 7 (depends on 6)

The isolated cell of claim 6, wherein the cell is a bacterial cell.

### Claim 8 (depends on 6)

The isolated cell of claim 6, wherein the cell is a eukaryotic cell.

### Claim 9 (depends on 8)

The isolated eukaryotic cell of claim 8, wherein the cell is a Chinese Hamster Ovary (CHO) cell.

### Claim 10 (depends on 8)

The isolated eukaryotic cell of claim 8, wherein the cell does not express J-chain.

### Claim 11 (depends on 10)

The isolated eukaryotic cell of claim 10, wherein the cell produces a pentameric IgM antibody.

### Claim 12 (depends on 10)

The isolated eukaryotic cell of claim 10, wherein the cell produces more pentameric IgM than hexameric IgM.

### Claim 13 (depends on 10)

A method of making an antibody or antigen-binding fragment thereof that specifically binds to human GD2 and includes a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 12, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 26, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 28, comprising culturing the isolated eukaryotic cell of claim 10 under conditions suitable to produce the antibody or antigen-binding fragment thereof and recovering the antibody or antigen-binding fragment thereof from the cell culture.

### Claim 14 (depends on 6)

A method of making an antibody or antigen-binding fragment thereof that specifically binds to human GD2 and includes a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 12, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 26, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 28, comprising culturing the isolated cell of claim 6 under conditions suitable to produce the antibody or antigen-binding fragment thereof and recovering the antibody or antigen-binding fragment thereof from the cell culture.

### Claim 15

A recombinant polynucleotide encoding an antibody heavy chain, or a fragment thereof, of an antibody that specifically binds to human GD2, wherein the heavy chain CDR1 of the antibody comprises the amino acid sequence of SEQ ID NO: 10, the heavy chain CDR2 of the antibody comprises the amino acid sequence of SEQ ID NO: 11, and the heavy chain CDR3 of the antibody comprises the amino acid sequence of SEQ ID NO: 12, wherein the encoded heavy chain or fragment thereof comprises SEQ ID NOs: 10, 11, and 12.

### Claim 16 (depends on 15)

The recombinant polynucleotide of claim 15, comprising the nucleic acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.

### Claim 17 (depends on 15)

The recombinant polynucleotide of claim 15, comprising the nucleic acid sequence of SEQ ID NO: 8.

### Claim 18 (depends on 15)

The recombinant polynucleotide of claim 15, comprising the nucleic acid sequence of SEQ ID NO: 39.

### Claim 19 (depends on 15)

A vector comprising the recombinant polynucleotide of claim 15.

### Claim 20 (depends on 19)

An isolated cell comprising the vector of claim 19.

### Claim 21 (depends on 20)

The isolated cell of claim 20, wherein the cell is a bacterial cell.

### Claim 22 (depends on 20)

The isolated cell of claim 20, wherein the cell is a eukaryotic cell.

### Claim 23 (depends on 22)

The isolated eukaryotic cell of claim 22, wherein the cell is a Chinese Hamster Ovary (CHO) cell.

### Claim 24

An isolated cell comprising a vector having a recombinant polynucleotide encoding an antibody heavy chain, or a fragment thereof, of an antibody that specifically binds to human GD2, wherein the encoded heavy chain or fragment thereof includes a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:10, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:11, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:12, the isolated cell further comprising a separate vector having a recombinant polynucleotide encoding an antibody light chain, or a fragment thereof, of an antibody that specifically binds to human GD2, wherein the encoded light chain or fragment thereof includes a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:26, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:28.

### Claim 25 (depends on 24)

A method of making an antibody or antigen-binding fragment thereof that specifically binds to human GD2 and includes a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 12, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 26, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 28, comprising culturing the isolated cell of claim 24 under conditions suitable to produce the antibody or antigen-binding fragment thereof and recovering the antibody or antigen-binding fragment thereof from the cell culture.

### Claim 26 (depends on 25)

The method of claim 25, wherein the isolated cell is a eukaryotic cell that does not express J-chain.

### Claim 27 (depends on 26)

The method of claim 26, wherein the antibody is a recombinant pentameric IgM antibody.

### Claim 28 (depends on 26)

The method of claim 26, wherein the isolated cell produces more pentameric IgM than hexameric IgM.
